Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 31 articles:
HTML format
Text format



Single Articles


    April 2017
  1. LU S, Dong Z
    Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
    Int J Oncol. 2017 Apr 19. doi: 10.3892/ijo.2017.3964.
    PubMed     Text format     Abstract available


    March 2017
  2. QIAN B, Yao Y, Liu C, Zhang J, et al
    SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.
    Int J Oncol. 2017 Mar 22. doi: 10.3892/ijo.2017.3926.
    PubMed     Text format     Abstract available


    February 2017
  3. LI W, Li Y, Li G, Zhou Z, et al
    Ectopic expression of the ATP synthase beta subunit on the membrane of PC-3M cells supports its potential role in prostate cancer metastasis.
    Int J Oncol. 2017 Feb 16. doi: 10.3892/ijo.2017.3878.
    PubMed     Text format     Abstract available


  4. WORST TS, Meyer Y, Gottschalt M, Weis CA, et al
    RAB27A, RAB27B and VPS36 are downregulated in advanced prostate cancer and show functional relevance in prostate cancer cells.
    Int J Oncol. 2017 Feb 10. doi: 10.3892/ijo.2017.3872.
    PubMed     Text format     Abstract available


  5. HUANG Y, Tao T, Liu C, Guan H, et al
    Upregulation of miR-146a by YY1 depletion correlates with delayed progression of prostate cancer.
    Int J Oncol. 2017;50:421-431.
    PubMed     Text format     Abstract available


    December 2016
  6. HUANG H, Du T, Xu G, Lai Y, et al
    Matrine suppresses invasion of castration-resistant prostate cancer cells by downregulating MMP-2/9 via NF-kappaB signaling pathway.
    Int J Oncol. 2016 Dec 14. doi: 10.3892/ijo.2016.3805.
    PubMed     Text format     Abstract available


  7. HARTING T, Stubbendorff M, Willenbrock S, Wagner S, et al
    The effect of dichloroacetate in canine prostate adenocarcinomas and transitional cell carcinomas in vitro.
    Int J Oncol. 2016;49:2341-2350.
    PubMed     Text format     Abstract available


    October 2016
  8. LI K, Mao Y, Lu L, Hu C, et al
    Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel.
    Int J Oncol. 2016;49:1679-85.
    PubMed     Text format     Abstract available


    September 2016
  9. PAN XW, Gan SS, Ye JQ, Fan YH, et al
    SMC1A promotes growth and migration of prostate cancer in vitro and in vivo.
    Int J Oncol. 2016 Sep 19. doi: 10.3892/ijo.2016.3697.
    PubMed     Text format     Abstract available


  10. YI X, Zhang J, Yan F, Lu Z, et al
    Synthesis of IR-780 dye-conjugated abiraterone for prostate cancer imaging and therapy.
    Int J Oncol. 2016 Sep 16. doi: 10.3892/ijo.2016.3693.
    PubMed     Text format     Abstract available


    August 2016
  11. KHURANA N, Talwar S, Chandra PK, Sharma P, et al
    Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
    Int J Oncol. 2016 Aug 2. doi: 10.3892/ijo.2016.3641.
    PubMed     Text format     Abstract available


    June 2016
  12. LI J, Yang X, Guan H, Mizokami A, et al
    Exosome-derived microRNAs contribute to prostate cancer chemoresistance.
    Int J Oncol. 2016 Jun 3. doi: 10.3892/ijo.2016.3560.
    PubMed     Text format     Abstract available


  13. WANG L, Fu P, Zhao Y, Wang G, et al
    Dissociation of NSC606985 induces atypical ER-stress and cell death in prostate cancer cells.
    Int J Oncol. 2016 Jun 2. doi: 10.3892/ijo.2016.3555.
    PubMed     Text format     Abstract available


    May 2016
  14. YIN B, Zhang M, Zeng Y, Li Y, et al
    [Corrigendum] Downregulation of cytokeratin 18 is associated with paclitaxelresistance and tumor aggressiveness in prostate cancer.
    Int J Oncol. 2016 May 30. doi: 10.3892/ijo.2016.3545.
    PubMed     Text format     Abstract available


  15. OKATO A, Goto Y, Kurozumi A, Kato M, et al
    Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in prostate cancer.
    Int J Oncol. 2016 May 16. doi: 10.3892/ijo.2016.3522.
    PubMed     Text format     Abstract available


  16. JI W, Chen J, Mi Y, Wang G, et al
    Platelet-activating factor receptor activation promotes prostate cancer cell growth, invasion and metastasis via ERK1/2 pathway.
    Int J Oncol. 2016 May 12. doi: 10.3892/ijo.2016.3519.
    PubMed     Text format     Abstract available


  17. MITRAN B, Varasteh Z, Selvaraju RK, Lindeberg G, et al
    Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
    Int J Oncol. 2016;48:2124-34.
    PubMed     Text format     Abstract available


    April 2016
  18. WANG J, Yi S, Zhou J, Zhang Y, et al
    The NF-kappaB subunit RelB regulates the migration and invasion abilities and the radio-sensitivity of prostate cancer cells.
    Int J Oncol. 2016 Apr 25. doi: 10.3892/ijo.2016.3500.
    PubMed     Text format     Abstract available


  19. MORO L, Arbini AA, Marra E, Greco M, et al
    [Corrigendum] Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2.
    Int J Oncol. 2016 Apr 14. doi: 10.3892/ijo.2016.3487.
    PubMed     Text format     Abstract available


  20. OGURA T, Tanaka Y, Tamaki H, Harada M, et al
    Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
    Int J Oncol. 2016 Apr 8. doi: 10.3892/ijo.2016.3482.
    PubMed     Text format     Abstract available


    March 2016
  21. DOMINSKA K, Ochedalski T, Kowalska K, Matysiak-Burzynska ZE, et al
    Interaction between angiotensin II and relaxin 2 in the progress of growth and spread of prostate cancer cells.
    Int J Oncol. 2016 Mar 24. doi: 10.3892/ijo.2016.3458.
    PubMed     Text format     Abstract available


  22. HU K, Tian Y, Du Y, Huang L, et al
    Atrazine promotes RM1 prostate cancer cell proliferation by activating STAT3 signaling.
    Int J Oncol. 2016 Mar 10. doi: 10.3892/ijo.2016.3433.
    PubMed     Text format     Abstract available


    February 2016
  23. YIN B, Zhang M, Zeng Y, Li Y, et al
    Downregulation of cytokeratin 18 is associated with paclitaxelresistance and tumor aggressiveness in prostate cancer.
    Int J Oncol. 2016 Feb 17. doi: 10.3892/ijo.2016.3396.
    PubMed     Text format     Abstract available


  24. ZHOU P, Ma L, Zhou J, Jiang M, et al
    miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells.
    Int J Oncol. 2016 Feb 15. doi: 10.3892/ijo.2016.3392.
    PubMed     Text format     Abstract available


  25. LI Q, Li Y, Wang Y, Cui Z, et al
    Quantitative proteomic study of human prostate cancer cells with different metastatic potentials.
    Int J Oncol. 2016 Feb 4. doi: 10.3892/ijo.2016.3378.
    PubMed     Text format     Abstract available


    January 2016
  26. LIANG YX, Lu JM, Mo RJ, He HC, et al
    E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer.
    Int J Oncol. 2016 Jan 29. doi: 10.3892/ijo.2016.3364.
    PubMed     Text format     Abstract available


  27. GU H, Liu T, Cai X, Tong Y, et al
    [Corrigendum] Upregulated LMO1 in prostate cancer acts as a novel coactivator of the androgen receptor.
    Int J Oncol. 2016 Jan 18. doi: 10.3892/ijo.2016.3344.
    PubMed     Text format     Abstract available


    November 2015
  28. GROSSEBRUMMEL H, Peter T, Mandelkow R, Weiss M, et al
    Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways.
    Int J Oncol. 2015 Nov 27. doi: 10.3892/ijo.2015.3274.
    PubMed     Text format     Abstract available


  29. WANG M, Ren D, Guo W, Huang S, et al
    N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells.
    Int J Oncol. 2015 Nov 26. doi: 10.3892/ijo.2015.3270.
    PubMed     Text format     Abstract available


  30. FUJIWARA J, Sowa Y, Horinaka M, Koyama M, et al
    [Corrigendum] The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.
    Int J Oncol. 2015 Nov 25. doi: 10.3892/ijo.2015.3265.
    PubMed     Text format     Abstract available


    April 2015
  31. LI Y, Wu Y, Abbatiello TC, Wu WL, et al
    Slug contributes to cancer progression by direct regulation of ERalpha signaling pathway.
    Int J Oncol. 2015;46:1461-72.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: